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For Jurkat cells in culture exposed to cisplatin (1), we measured the number of platinum
adducts on DNA and showed that it is proportional to the AUC, the area under the concentration
vs time curve, for cisplatin. The number of platinum-DNA adducts is measured immediately
following exposure to drug. The AUC is calculated either as the product of the initial cisplatin
concentration and the exposure time or as the integral under the concentration vs time curve
for the unreacted dichloro species, which decreases exponentially. We also show that the number
of adducts correlates with decreases in respiration, with the amount of DNA fragmentation,
and with cell viability, all measured 24 h after exposure to the drug. To study the reactions of
cisplatin at concentrations approaching clinical relevance (65 µM), we use two-dimensional
[1H15N]HSQC NMR and the 15N-labeled form of the drug, cis-Pt(15NH3)2Cl2, 1. In the absence
of cells, 1 reacts with components of the growth medium and also transforms slowly (kh )
0.205 h-1 at 37 °C) into the chloro-aquo species, cis-[Pt(15NH3)2Cl(H2O)]+ (2), which at the pH
of the medium (pH 7.15), is mainly in the deprotonated chloro-hydroxy form, cis-Pt(15NH3)2-
Cl(OH) (4). The concentration of 2 (4), as measured by HSQC NMR, decreases due to reaction
with components of the medium. In the presence of 5 million or more cells, the concentration
of 1 decreases with time, but the NMR signal for 2 (4) is not seen because it is rapidly removed
from solution by the cells, keeping its concentration very low. These experiments confirm that
the species preferentially removed from the medium by cells is 2 (4) and not 1. Our findings
are discussed in the context of a kinetic model for platination of nuclear DNA by cisplatin,
which includes aquation of cisplatin outside the cell, passage of 2 (4) through the cell membrane,
reaction of reactive platinum species (RPS) in the cytosol with thiols, formation of adducts
between RPS and accessible sites on genomic DNA, and removal of platinum from DNA by
repair. Some of the rate constants involved are measured, but others can only be estimated.
Calculations with this model show that little of the platinum reacts with intracellular thiols
before reaching the nuclear DNA, indicating that binding to thiols is not important in cisplatin
resistance. The model also predicts the circumstances under which the amount of platination
of nuclear DNA is proportional to AUC.
Introduction
Cisplatin, cis-dichlorodiammineplatinum (II),1 is in
wide clinical use for the treatment of a variety of cancers
(1). A major problem with cisplatin therapy is the
resistance associated with extended use of the drug (2).
Because cisplatin-induced apoptosis is related to the
amount of platinum (Pt) bound to genomic DNA, cellular
mechanisms that reduce the number of Pt-DNA adducts
are the main factors affecting cisplatin resistance. These
include DNA repair (2, 3), efflux of Pt from cells (4-6),
and reaction of the drug with glutathione (GSH) and
metallothionein (MT) (2, 7-9). More recently, it has been
shown that other biochemical processes, not directly
related to platination of DNA, may also contribute to
resistance. For example, thiolate adducts of cisplatin that
form in the cytoplasm may affect the thiol/disulfide
equilibrium thus blocking the cell from entering into
apoptosis (10-12).
For cell cycle nonspecific drugs such as cisplatin,
Ozawa et al. (13) showed that cytotoxicity is proportional
to the product of the exposure time and extracellular drug
concentration, referred to as the area under the curve or
AUC. It is often the case that AUC is the important
parameter in determining the antitumor activity of
cisplatin and other drugs (14-17) although exceptions
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are also well-known (18, 19). In addition to establishing
the validity of AUC for cisplatin in different cell types,
modeling the cytotoxicity of the drug using experimental
rate data for binding/transfer events in the cell has also
been attempted. Miyagi et al. (20) constructed a model
to explain the cytocidal and DNA binding effects of
nedaplatin, a cisplatin analogue. Their model included
drug transport across the cell membrane and drug
reaction with DNA and assumed cell death occurred
when the percentage of DNA-Pt adducts exceeded a
threshold. Assuming rate constants for the processes, the
coupled differential equations were solved to obtain the
percent of cells killed as a function of time and drug
concentration in the extracellular fluid. In modeling
cisplatin cytotoxicity, El-Kareh and Secomb (18) consid-
ered the uptake, efflux, DNA binding, and repair rates
of the drug to produce a model that provided good fits to
experimental data sets, including exposure times of ∼100
h. Recently, we proposed a model for cisplatin binding
to genomic DNA (21). Our model included transfer of
cisplatin across the cell and nuclear membranes, plati-
nation of DNA, and reaction of cisplatin with cellular
thiols and cellular drugs. The amount of Pt bound to DNA
was calculated by solving coupled differential equations,
assuming values for rate constants that gave agreement
between calculated and measured results, since mea-
sured values for some of them were not available.
In an earlier study (22), we showed that alteration in
mitochondrial function is a secondary effect of cisplatin
cytotoxicity in Jurkat cells in culture. In this report, we
simulate continuous injection of cisplatin by exposing
Jurkat cells to different concentrations of the drug for
different periods of time. We show that the AUC cor-
relates with the amount of Pt bound to DNA immediately
after drug exposure and with changes in cellular respira-
tion, viability, and DNA fragmentation observed 24 h
after exposure. Using two-dimensional (2D) [1H15N] het-
eronuclear single quantum cohearence (HSQC) NMR and
the 15N-labeled form of the drug, cis-Pt(15NH3)2Cl2 (1)
(Figure 1), we identify the cisplatin species preferentially
removed from the culture medium by the cells. Although
not so far employed for cell studies involving cisplatin,
HSQC NMR has been used to characterize solution
chemistry and reaction products of cisplatin and some
of its analogues (23-31). We find that in the cell culture
medium at pH 7.15, cisplatin aquates to produce the
chloro-aquo complex, cis-[Pt(15NH3)2(H2O)Cl]+ (2), which
is in equilibrium with the chloro-hydroxy compound, cis-
Pt(15NH3)2(OH)Cl (4) (Figure 1). The HSQC NMR studies
show that compared to 1, the mono-aquated product, 2
(4), is more readily removed from the medium by the
cells.
This and other information are used to improve our
kinetic model of Pt binding to genomic DNA. The aqua-
tion of 1 to 2 is included (the rate constant is known) as
well as the uptake of 2 and 4 by cells (with measured
rate constants). In addition to helping to explain Pt
binding to DNA and the AUC data, the model should
provide a framework for understanding Pt cytotoxicity
to cancer and normal cells. Suitably parametrized, it
could then be used to suggest dosing protocols for Pt
anticancer drugs, which maximize cancer cell kill while
minimizing damage to normal cells.
Materials and Methods
Chemicals. All materials were reagent grade and used as
supplied. Cisplatin (3.3 mM in 154 mM aqueous NaCl) was
obtained from American Pharmaceutical Partners (Los Angeles,
CA); the Pd(II) complex of meso-tetra(4-sulfonatophenyl)tetra-
benzoporphyrin (Pd phosphor), sodium salt, was purchased from
Porphyrin Products, Inc. (Logan, UT); proteinase k, ribonuclease
A (DNase-free from bovine pancreas; contained ∼80 units/mg),
rotenone, adenosine 5′-diphosphate (ADP), bromophenol blue,
xylene cyanol FF, and fatty acid free bovine serum albumin
(BSA) were purchased from Sigma-Aldrich (St. Louis, MO);
nonyl phenyl-poly(ethylene glycol) (Nonidet NP-40) was pur-
chased from Fluka (Ronkonkoma, NY); agarose (molecular
biology grade) was purchased from Promega (Madison, WI);
Dulbecco’s phosphate-buffered saline (PBS; w/o calcium or
magnesium), fetal bovine serum (FBS), and RPMI-1640 medium
with L-glutamine (pH 7.15) were purchased from Mediatech
(Herndon, VA); DNA HyperLadder I [200-10 000 base pair (bp)]
was purchased from Bioline USA Inc. (Randolph, MA). cis-Pt-
(15NH3)2Cl2 was synthesized from K2PtCl4 (Sigma-Aldrich) and
15NH4CO2CH3 (Cambridge Isotope Laboratories, Inc., Andover,
MA) using an earlier reported procedure (32). The 15N-labeled
drug was recryctallized from boiling 0.1 M HCl.
Solutions. The Pd phosphor for the respiration studies was
dissolved in distilled deionized water (dH2O) (2.5 mg/mL or ∼2.0
mM) and stored in the refrigerator for less than 2 weeks.
Rotenone (1.0 mM) was freshly dissolved in absolute ethanol.
Phosphate-citrate buffer consisted of 200 mM Na2HPO4, with
the pH adjusted to 7.8 with 0.1 M citric acid. Proteinase k (20
mg/mL) and ribonuclease A (10 mg/mL) solutions were made
in dH2O and stored at -20°C. Nonidet NP-40 0.25% (v/v)
solution was made in dH2O and stored at room temperature
(RT). Gel loading buffer contained (v/v) 0.25% bromophenol blue,
0.25% xylene cyanol FF, and 30% glycerol in dH2O. Tris-
borate-EDTA (TBE) buffer contained 40 mM Tris, boric acid,
and 2 mM EDTA (pH 8.3).
The Pd phosphor solution for the respiration experiments
contained 2 µM Pd phosphor, 2% (w/v) BSA, and 5 mM ADP in
RPMI (containing ∼6 mM Na2HPO4 and 10 mM glucose); the
final pH was ∼7.5. The solution was freshly made in a 30 mL
quartz tube and continuously stirred for at least 90 min prior
to use.
Cells. The human T-cell lymphoma cell line, Jurkat, was a
gift from Dr. Edward Barker. The cells were maintained in
suspension culture under a fully humidified atmosphere con-
taining 5% CO2 at 37 °C. The medium was RPMI-1640 supple-
mented with 10% (v/v) FBS, 100 µg/mL streptomycin, 100 IU/
mL penicillin, and 2.0 mM L-glutamine. The number of cells
and their viability were determined immediately prior to
experimental measurements by light microscopy, using a he-
macytometer under standard trypan blue staining conditions
(33).
Figure 1. Aquation of cisplatin. The values for the pKa values
are from ref 31.
Pharmacodynamics of Cisplatin Chem. Res. Toxicol., Vol. 17, No. 11, 2004 1435
Incubation of Cells with Cisplatin. Incubations were
carried out in RPMI medium plus 10% FBS at 37 °C. Cells in
logarithmic growth (∼107/condition) were exposed to cisplatin
using times and drug concentrations indicated in Table 1. At
the end of the incubation periods, the cells were collected by
centrifugation, washed, and analyzed immediately for Pt-DNA
adducts or maintained in culture (drug-free medium) and
analyzed 24 h later, for respiration, viability, and DNA frag-
mentation.
Pt-DNA Adducts. Cellular (genomic) DNA was extracted
from Jurkat cells immediately following the incubations with
cisplatin. Pt-DNA adducts per 106 nucleotides (nts) (Table 1)
were determined by atomic absorption spectroscopy (AAS) as
previously described (21).
Cellular Oxygen Consumption. Respiration was measured
at RT in sealed vials containing cells suspended in 0.7 mL of
the Pd phosphor solution 24 h after exposure to cisplatin. The
substrate for the cells was glucose. The concentration of oxygen
[O2] in the solution was measured as a function of time using
the phosphorescence probe, Pd phosphor (34, 35). This method
was based on oxygen quenching of phosphorescence of the Pd
phosphor.
The rate of cellular mitochondrial oxygen consumption (µM
O2 min-1) was calculated as the negative slope of the linear
portion ([O2] g 150 µM) of the [O2] vs time curves. The value of
k, a zero-order rate constant, was set equal to the negative slope
of each curve divided by the total number of cells (in millions)
in each sample. Each experiment included a measurement in
the presence of rotenone (which inhibits complex I of the
respiratory chain). The rate of oxygen consumption for the Pd
phosphor solution without cells was (mean ( SD) 0.28 ( 0.05
µM O2 min-1 and, for ∼107 cells incubated with rotenone (50
µM at 37 °C for 1 h), 0.36 ( 0.16 µM O2 min-1.
Extraction of DNA Fragments. DNA fragments were
extracted as described (36) with some modifications. Cells were
washed with PBS and suspended in 1.0 mL of ice-cold PBS. Cells
(∼3 × 106/condition) were fixed in 8.0 mL of ice-cold 70%
ethanol. The suspension was incubated at -20 °C for 24 h and
then centrifuged (1000g for 5 min at 4 °C). The supernatant
was discarded, and the ethanol was allowed to completely
evaporate at RT. The pellet was suspended in 50 µL of
phosphate-citrate buffer and incubated at 20 °C for 90 min. The
suspension was centrifuged (as above), and the supernatant was
transferred to a fresh tube. The supernatant was recentrifuged
as above, and the supernatant was lyophilized in a Speed Vac.
The lyophilized pellet was suspended in 6 µL of Nonidet NP-40
(0.25% solution), 6 µL of SDS (10%), 6 µL of ribonuclease A (10
mg/mL solution), and 2 µL of ribonuclease T1. After overnight
incubation at 37 °C, 6 µL of proteinase k (20 mg/mL solution)
was added and the mixture was incubated overnight. Twenty-
four microliters of the gel-loading buffer was added (final volume
∼50 µL).
Agarose Gel Electrophoresis. Approximately 22 µL of the
above extract was loaded on 4 mm thick, 1.0% agarose gels, and
electrophoresed at 25 V and 11 mA for ∼15 h in TBE buffer.
Each extract was loaded on two separated gels. The gels were
stained in 300 mL of 0.5 µg/mL ethidium bromide for 30 min in
the dark at RT. After destaining for 15 min in dH2O, the gels
were stored at 4 °C in 300 mL of TBE. The images were captured
using a Gel Doc digital camera system with Quantity One
software (Bio-Rad, Richmond, CA).
Quantitation of Stained Gels. The digital image of the
stained gel was captured after adjusting the exposure time and
iris diaphragm of the camera so that the maximum pixel
intensity was below saturation (22). The digital image was
analyzed using Sigma Scan software (version 2.0, SPSS Inc.).
Individual lanes were scanned from the loading well to the low
molecular weight end of the streaks. Net intensity vs position
plots were exported to Peak-Fit software (version 4.1, SPSS
Inc.), and the total intensity in the range of 0.1-10.0 kilo base
pair (kb) (in arbitrary units) for each lane was determined.
HSQC NMR. The 2D [1H15N]HSQC NMR spectra were
recorded at 37 °C using Bruker ADVANCE 500 and 600
spectrometers equipped with triple axes probes. The frequencies
used were as follows: 1H, 500.13 and 600.13 MHz; 15N, 50.646
and 60.81 MHz. The spectra, optimized for 1J(15N-1H) ) 72 Hz,
were recorded using a pulse sequence available in the Bruker
software package. The NMR experiment was 2D, 1H-15N, with
inverse detection, phase sensitive with ECHO/Antiecho-TPP1
gradient selection, with decoupling during acquisition. Samples
were not spun during the experiment. Twenty NMR experi-
ments (each 62 min in length, ns ) 48) were conducted for each
kinetic run with 1. For each NMR experiment, there were 1K
data points in the proton dimension and 64 t1 values. The sweep
widths in the proton and nitrogen dimensions were 4006.41
(8.01 ppm) and 4054.06 (80 ppm), respectively. Processing
included squared cosine apodization in both dimensions, and
zerofilling along the remote dimension to create a symmetric
matrix (1K × 1K). For some experiments, 15 to -115 ppm on
the 15N axis was searched. Peak volumes [the 195Pt satellites of
cis-Pt(15NH3)Cl2 were not included] were calculated using
Bruker software, and the volumes analyzed in the manner
described in the text.
The 15N chemical shifts were referenced externally to 1 M
(15NH4)2SO4, in 95/5 H2O/deuterium oxide (D2O), which was
acidified to pH ∼1 by addition of H2SO4. The 1H chemical shift
of 1 relative to Me3SiCD2CD2CO2Na, TSP, in a pH 7.15, 23 mM
sodium bicarbonate buffer, was 4.09 ppm.
Each NMR sample was prepared so that it contained 5%
added D2O. This permitted locking onto deuterium with minimal
loss of the signal intensity from hydrogen/deuterium exchange
of the Pt complexes. The NMR studies were carried out in RPMI-
1640 (pH 7.15) supplemented with 10% (v/v) FBS, 100 µg/mL
streptomycin, 100 IU/mL penicillin, and 2.0 mM L-glutamine.
The chloride concentration in the medium was ∼105 mM, and
the final volume in the NMR tube was 920 µL. Concentrations
of stock solutions of labeled cisplatin were determined by AAS.




















0 3.0 0 4.7 ( 2.7 96 ( 2.0 0.37 ( 0.12 9.6 ( 3.1
5 3.0 11.2 9.0 ( 3.5 91 ( 1.0 0.38 ( 0.18 13.1 ( 6.2
10 1.5 12.9 5.9 ( 1.6 92 ( 0.6 0.33 ( 0.09 14.1 ( 6.8
15 1.0 13.6 6.7 ( 1.5 93 ( 3.0 0.33 ( 0.07 14.1 ( 7.4
15 3.0 33.6 24.9 ( 8.0 83 ( 1.0 0.18 ( 0.00 30.6 ( 4.8
30 1.5 38.7 26.3 ( 5.0 86 ( 1.7 0.20 ( 0.01 28.6 ( 1.2
45 1.0 40.7 27.6 ( 15.0 86 ( 3.5 0.22 ( 0.03 26.9 ( 9.0
25 3.0 56.0 46.7 ( 11.8 70 ( 4.4 0.15 ( 0.02 36.5 ( 0.8
50 1.5 64.6 37.5 ( 10.6 76 ( 4.4 0.13 ( 0.01 29.0 ( 9.5
75 1.0 67.8 36.5 ( 12.0 76 ( 2.6 0.17 ( 0.01 37.4 ( 5.5
a Cells (∼107 per condition) were incubated at 37 °C with the indicated [cisplatin] for the indicated period of time. At the end of the
incubation periods, the cells were collected by centrifugation, washed, and analyzed immediately for Pt-DNA adducts or maintained in
culture (drug-free medium) and analyzed 24 h later, for respiration, viability, and DNA fragmentation as described in the Materials and
Methods. The numbers are the means ( SD of 2-3 experiments.
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The kinetics of reaction of cisplatin in the absence of cells
was measured using a solution containing 65 µM cis-Pt(15NH3)2-
Cl2 (1) (Figure 1). The assignment of peaks that appear when 1
reacts in culture medium in the absence of cells was done by
reference to the literature (31) and by collecting NMR data on
solutions of cisplatin that were “aged” by allowing 4.2 mM 1 to
stand for 24 h in 10 mM NaCl. This produces a mixture of 1
and its aquated forms 2 and 3 (31). A portion of the aged solution
was added to the culture medium to give a concentration of 65
µM Pt, and NMR data for 1 h were obtained. The spectrum
exhibited the same peaks as those observed when 1 hydrolyzes
in culture medium, but the relative intensities of the peaks for
1 and 2 (4) were different, with more of the mono-aquo present
in the aged samples. Peak assignments for the mono-aquated
complex were further confirmed by determining the 2D HSQC
NMR spectrum of an aged solution (described above) of cisplatin
in 23 mM NaHCO3 buffer (pH 7.15). Acidification of this solution
with 1 N HNO3 to values of pH in the range of 7.15 to ∼5
produced NMR spectra consistent with the earlier published
assignments for 2 and 4 (31). This also confirmed that at pH
7.15, the peaks for 1 and 4b overlap.
The kinetics of reaction of cisplatin in the culture medium
with ∼1.5 × 107 cells was measured using a solution containing
65 µM 1. The stock solution of drug in 154 mM aqueous NaCl
was added to the cells in the medium, the suspension was mixed
by pipet action, and the resulting mixture was added to the
NMR tube.
On separate samples under NMR conditions in sealed tubes,
cell viability was checked every hour for the first 8 h of the
kinetic run and again at the end of the run, ∼21 h. The
viabilities of drug-treated and untreated cells were virtually the
same, 91.8 ( 5.0 vs 94.7 ( 2.3%, respectively, during the first
8 h. At the end of the ∼21 h exposure period, the viabilities
were low but there was a measurable difference between
untreated (27.5 ( 7.8%) and treated cells (10.0 ( 7.1%).
Moreover, at the end of the ∼21 h exposure period, untreated
cells respired twice as fast and had ∼50% fewer DNA fragments
than cells treated with cisplatin under NMR-like conditions
(data not shown).
Results
Effect of AUC on Pt-DNA Adduct Formation by
Cisplatin. Pt-DNA adducts were measured at the end
of the incubation periods indicated in Table 1. The
amount of Pt-DNA adducts is plotted vs AUC, calculated
as the product of the cisplatin concentration ([cisplatin])
(µM) and the exposure time (h), in Figure 2 (upper panel).
DNA platination increased linearly with AUC (dashed
line, R2 > 0.94). Jurkat cells treated with an AUC ) 15
µM h (5 µM for 3 h, 10 µM for 1.5 h, or 15 µM for 1 h)
produced ∼5.9-9.0 Pt adducts per 106 nts. For AUC )
45 µM h (15 µM for 3 h, 30 µM for 1.5 h, or 45 µM for 1
h), the amount of Pt-DNA adducts was 3-4 times
higher, and for AUC ) 75 µM h, DNA platination
increased by a factor of 4-5.
The calculation of AUC as concentration × time, T, is
appropriate when the [cisplatin] is maintained constant,
as in administering the drug by infusion into plasma.
However, the NMR results (see below) show that in our
experiments, the concentration of 1 decreased exponen-
tially, [cisplatin] ) (65 µM) e-kt, because of formation of
the mono-aquated product 2 (4) and uptake of the latter
by the cells, with a hydrolysis rate constant kh of 0.205
h-1. Thus, the AUC can also be calculated as ∫ C dt )
(CC/k)(1 - e-kT) where CC is the initial concentration of
1. A plot of the amount of Pt-DNA adducts vs AUC
calculated in this way (“true AUC”) is shown in the lower
panel of Figure 2, with the best linear fit. Although R2 is
slightly decreased (to 0.91), the fit is well within experi-
mental error.
During the incubation periods with cisplatin, Pt-DNA
adducts are continuously formed and removed (1, 2).
Inhibition of the nucleotide excision repair mechanism
has been shown to increase adduct levels ∼2-fold (37).
Thus, the Pt-DNA adducts that we measured were a net
value representing the difference between the number
of adducts formed and the number of adducts removed
by repair.
Effects of AUC on Cisplatin-Induced Impair-
ments of Cellular Respiration, DNA Fragmenta-
tion, and Loss of Cell Viability. The dependence of
cellular mitochondrial oxygen consumption (measured 24
h after drug exposure) on AUC is shown in Table 1. A
representative [O2] vs time curve for each AUC value is
shown in Figure 3. The rate of respiration decreases
linearly with AUC (0-67.8 µM h, R > 0.95).
The effects of the AUC on cisplatin-induced DNA
fragmentation measured 24 h after exposure to the drug
are summarized in Table 1 and shown in Figure 4. The
amount of fragmented DNA increases almost linearly (R
> 0.94) as a function of AUC. The percentage of viable
cells (mean ( SD) 24 h after exposure to drug is also
given in Table 1. The percentage of viable cells decreases
linearly with R > 0.96 (plots not shown).
HSQC NMR. These experiments showed that the
amount of Pt bound to DNA, as well as other cytotoxicity
parameters described above, were proportional to AUC.
Figure 2. Dependence of DNA-Pt adduct formation on AUC.
Two experiments were done with 15 million cells per condition,
incubated at 37 °C for the times and cisplatin concentrations
indicated in Table 1. The upper panel shows the number of Pt-
DNA adducts in cells incubated with cisplatin solution vs AUC,
calculated as the product of [cisplatin] CC (µM) and exposure
time T (h). The least-squares linear fit (dashed line) is ) 0.52
+ 1.40(AUC) with R2 ) 0.95. The lower panel shows the number
of Pt-DNA adducts (with experimental error bars) vs true AUC,
calculated as product of CC and (1 - e-kT)/k, where k ) 0.205
h-1. The least-squares linear fit (dashed line) is 0.60 + 2.22-
(AUC) with R2 ) 0.91.
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The cisplatin species that formed in the culture medium
were next identified using HSQC NMR. The addition of
65 µM cis-Pt(15NH3)2Cl2 (1) to the cell culture medium
without cells at 37 °C resulted in the slow disappearance
of the peak for 1 at 1H/15N, δ ) 4.09/-68.0, and the
appearance of a new peak at 1H/15N, δ ) 3.61/-80.5
(Figure 5). On the basis of earlier published assignments
(31) and NMR data collected on “aged” solutions of 1 in
this work, the latter peak was assigned to 15NH3 trans
to the O of cis-Pt(15NH3)2(OH)Cl (4) (Figure 1). The peak
for 15NH3 trans to the Cl of 4 was at almost the same
position as the peak for the two labeled ammonia
molecules of 1 (29, 31). This gives rise to the asymmetric
peak at 1H/15N, δ ) 4.09/-68.0 (Figure 5). Because the
pKa for the deprotonation of 2 to form 4 is 6.41 (31), at
pH 7.15, the distribution of species is ∼15% 2 and ∼85%
4.
In the culture medium without cells, the intensity of
the cisplatin peak decreased exponentially with time (see
Figure 6). The intensity of the peak assigned to the
deprotonated aquated product 4 also decreased exponen-
tially but more slowly. No peaks other than those for 1
and 4 were observed in the spectra. When 5 million or
more cells are present, the intensity of the peak for 1
decreased with time (Figure 7), but the peak for 4 was
not observed. A new peak (1H/15N, δ ) 3.98/-62.0) of low
intensity appeared after several hours.
To further confirm that the peak assignments shown
in Figure 5 were correct, we measured the kinetics of
decrease of 1 in the culture medium. The intensity
(volume) of the peak at 1H/15N, δ ) 3.61/-80.5, was
subtracted from the intensity of the peak at δ ) 4.09/-
68.0, and the result was divided by 2 (two equal reso-
nances present for 1). Fitting the first nine points (t < 9
h) to an exponential gave 106.47 e-0.205t, so that the value
of the rate constant is kh ) 0.205 h-1 ) 5.7 × 10-5 s-1 at
37 °C, somewhat higher than the reported rate constant
for the hydrolysis of cisplatin at 25 °C, 5.18 × 10-5 s-1
(29).
Finally, we calculated the initial rate of decrease of [1]
by subtracting the intensity of the peak at 1H/15N, δ )
3.61/-80.5, from that of the cisplatin peak at each time
(t) and fitting the first six points to a line. Assuming the
initial concentration of 1 was 65 µΜ, the three experi-
ments shown in Figure 6 gave 5.6 ( 1.1, 7.9 ( 1.8, and
Figure 3. Dependence of AUC on cisplatin-induced mitochon-
drial dysfunction as measured by decreased cellular oxygen
consumption. An oxygen consumption curve for each AUC value
(0, diamonds; 13.6 µΜ h, squares; 38.7 µΜ h, triangles; and 56.0
µΜ h, circles) from a representative experiment is shown. Cells
(∼107 per condition) were incubated at 37 °C for the times and
cisplatin concentrations indicated in Table 1 and then main-
tained in drug-free medium for 24 h at 37 °C. At the end of the
incubation period, a small volume of each suspension was
removed to determine cell count and viability. The remaining
cells were washed with PBS, suspended in the Pd phosphor
solution, and placed in the instrument. The values of k were
calculated as described in the Materials and Methods. The
average (mean ( SD) values of k for each AUC value from three
independent experiments are shown in Table 1.
Figure 4. AUC dependence of cisplatin cytotoxicity as mea-
sured by DNA fragmentation. A representative gel is shown.
The experimental conditions were as described in the legend to
Table 1. Three experiments were done with results (mean (
SD) shown in Table 1. Lane 2 (from left): cells incubated with
no addition for 3 h (AUC ) 0). Lanes 3-5 are cells incubated
with AUC ) 11.2-13.6 µΜ h (lane 3, 5 µM, 3 h; lane 4, 10 µM,
1.5 h; and lane 5, 15 µM, 1 h). Lanes 6-8 correspond to AUC )
33.6-40.7 µΜ h (lane 6, 15 µM, 3 h; lane 7, 30 µM, 1.5 h; and
lane 8, 45 µM, 1 h). Lanes 9-11 correspond to AUC ) 56.0-
67.8 µΜ h (lane 9, 25 µM, 3 h; lane 10, 50 µM, 1.5 h; and lane
11, 75 µM, 1 h). Lane 1 is a DNA HyperLadder I (200-10 000
bp).
Figure 5. Two-dimensional [1H,15N]HSQC NMR (500 MHz)
spectrum of 65 µM cis-Pt(15NH3)2Cl2 in RPMI cell culture
medium, pH 7.15, at 37° C. Compound 1 is cis-Pt(15NH3)2Cl2,
and compound 4 is cis-Pt(15NH3)2(OH)Cl. (a) 15NH3 trans to OH;
(b) 15NH3 trans to Cl (see Figure 1 for structures). Asterisks
show the 195Pt satellites of 1. The spectrum was obtained 3 h
following the addition of 1 to the culture medium.
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9.3 ( 2.5 µM/h for the initial rate of decrease (standard
error of fit given). Averaging the three, we obtain 7.6 (
1.5 µM/h (average ( variance). Analysis of the data
shown in Figure 7 (15 million Jurkat cells present) in
the same way gave initial rates of decrease of 4.2 ( 0.8,
4.5 ( 1.6, and 5.8 ( 0.6 µM/h. Averaging the three, we
obtain 4.8 ( 0.7 µM/h (average ( variance). This is
significantly lower than the rate in the absence of cells.
However, if the data for all t values are fitted to
exponentials, the exponential parameter is essentially the
same in the presence and absence of cells.
The interpretation of these results is that 1 aquates
to produce 4 and also reacts with some components of
the culture medium. The species 4 also reacts with some
components of the culture medium, but because 4 is being
produced from 1, the apparent rate of decay of the
intensities for 4 is much slower. The products of the
reactions of 1 and 4 with the medium are not seen in
the NMR, either because the product molecules are of
very high molecular weight or because there are too many
different products and the concentration of any one is too
low to be detected in the experiment. In the presence of
15 million cells, the peak arising from 4 is not observed
in the HSQC NMR. In other experiments, not shown
here, we have observed this peak when fewer than 5
million cells are present. The peak’s absence indicates
that 4 is removed from solution by the cells more rapidly
than 1.
The identity of a new signal at 3.98/-62.0, which
appears after 8-10 h in the presence of cells, is unknown.
However, we note that measured cell viability remains
high for ∼12 h, but it decreases rapidly for 12-20 h,
indicating that apoptosis is taking place at these times.
This suggests that the signal at 3.98/-62.0 is associated
with a species formed by the reaction of 1 with compo-
nents released from the cells to the medium during
apoptosis.
Discussion
In this work, we show that the amount of Pt bound to
genomic DNA of Jurkat cells correlates linearly with the
AUC, calculated as the product of the initial concentra-
tion of cisplatin in the medium and the exposure time to
Figure 6. Integrated intensities (volumes) of NMR peaks as
functions of time in the absence of cells in culture medium. The
results of three experiments (65 µM, 1) are shown. Squares )
intensities for peak at 1H/15N, δ ) 4.09/-68.0, due to 1, and the
ammonia molecule trans to the Cl of 4; circles ) intensities for
peak at 1H/15N, δ ) 3.61/-80.5, due to the ammonia molecule
trans to the OH of 4; and dashed lines ) fit of intensities to
exponentials.
Figure 7. Integrated intensities (volumes) of NMR peaks as
functions of time in the presence of 15 million Jurkat cells.
Results of three experiments (∼10 h, top; ∼20 h, middle and
bottom) are shown. Squares ) intensities for peak at 1H/15N, δ
) 4.09/-68.0, due to 1; dashed lines ) exponential fits. The peak
at 1H/15N, δ ) 3.61/-80.5, seen in the absence of cells, never
appears.
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the drug. The correlation is slightly less good if the AUC
is calculated as ∫ C dt, where C is the actual [cisplatin].
The NMR experiments show that the drug (form 1) slowly
hydrolyzes to produce the mono-aquated form 2, which
at the pH of the medium, forms mainly the deprotonated
complex, 4. When 5 million or more cells are present in
the medium, the NMR studies indicate that hydrolysis
of 1 is occurring but 4 is not observed. That this signal
is not observed in the presence of cells could be due to
electrostatic or covalent binding of the mono-aquo com-
plex to the surface of the cell and/or to the reaction of
this compound with a high molecular weight molecule
in the cytoplasm.
Other workers have observed that aquated forms of
cisplatin are preferentially taken up by cells. Jennerwein
and Andrews (38) and later Howell and co-workers (39)
exposed human ovarian, head, and neck carcinoma cells
to mixtures containing the aquated forms of cisplatin and
measured the amount of Pt bound to DNA. They found
that as compared to cisplatin itself, aquated forms of the
drug are more effective at platinating DNA. In a later
study, Pereira-Maia and Garnier-Suillerot (40) showed
that the diaquated products, 5 and 6, compounds not
observed in our experiments, are taken up by small lung
cancer cells at a rate ∼40 times faster than cisplatin.
Although 5 and 6 are not likely to form in media with
high chloride concentrations, e.g., culture media or blood,
the compound appears to be actively pumped into the cell
by a transport mechanism. Recently, it has been shown
that proteins responsible for the transport of copper into
the cell may also be responsible for the active uptake of
Pt (5, 41). Clearly, determining the mechanism by which
2 (4) is removed from solution by Jurkat cells will require
additional study.
Although the rate of decrease of [1] over time is about
the same in the presence and absence of cells, the initial
rate of decrease of [1] is larger when no cells are present.
The reason for this may be that 1 reacts with some
components of the culture medium, as well as aquating
to 4, and that some of the components of the meduim
are absorbed by the cells at early times. The species 4
also reacts with components of the culture medium, but
because 4 is being formed from 1 at the same time, the
apparent rate of decrease of [4] is much smaller than that
of [1].
The most important observation is that 4 never ap-
pears when 5 million or more cells are present. This
shows that 4 is removed from solution by the cells much
faster than 1. The RPMI medium contains ∼3 µM GSH
and ∼370 µM cysteine, both of which are good nucleo-
philes for Pt. The fact that these compounds do not react
with Pt species to produce products having S trans to
15NH3 (δ 15N ∼ -40 ppm) (28) is an indication that in
the culture medium these thiols are in their less reactive
disulfide forms.
Theoretical Model
Having determined that platination is proportional to
AUC for Jurkat cells in culture and having found that
cells remove 2 (4) more efficiently than 1 from the
extracellular solution, we refined our kinetic model (21)
of cisplatin binding to cellular DNA. The model considers
the important processes involved in bringing extracellu-
lar Pt to nuclear DNA, where it forms the lesions, which
lead to apoptosis. The processes considered in the model
are shown in Figure 8 and discussed below. It is recog-
nized that each process may involve several chemical or
biochemical reactions.
(i) The first process is the aquation of the dichloro
species, 1, to 2, which becomes a mixture of 2 and 4. The
rate of aquation is khE, where E is the concentration of
1 and kh ) 0.205 h-1, as measured in the present study
and elsewhere (29). The reverse rate is ki[Cl-][2], where
ki can be calculated from kh and the measured equilib-
rium constant (29). (ii) As has been shown in this work,
the monoaquo compound 2 (4) is removed from the
extracellular solution by Jurkat cells. Ghezzi et al. (42)
have recently measured the amount of Pt taken up by
human MCF-7 breast cancer cells exposed to cisplatin.
They confirmed that the uptake rate is proportional to
E, even at high concentrations and times. Although they
did not determine the form of the Pt entering the cells,
it is reasonable to assume that it is the same as that
removed from the solution by the cells. We use the value
of the rate constant that they determined, kt ) 4.2 × 10-13
mol M-1 h-1 per cell. Measurements in our laboratory
with Jurkat cells exposed to cisplatin gave a similar value
for this rate constant (Centerwall and Tacka, personal
communication). The rate constant for Pt entering the
cell interior (as compared to becoming covalently bound
to the outside) is certainly smaller than 4.2 × 10-13 mol
M-1 h-1 per cell, but we know of no way to determine it.
This value of kt is multiplied by the number of cells and
divided by the reaction volume (Vreaction ) 20 mL) to get
the rate of decrease of extracellular Pt concentration or
divided by a cell volume (Vcell ) 1 pL) to obtain the rate
of increase of intracellular concentration. (iii) In the
cytosol, where [Cl-] is much lower than outside the cell,
free 2 (4) may lose chloride to form 5 (6). For the model,
we consider all species in the cytosol together as reactive
platinum species (RPS), the concentration of which (P)
is determined by kt and the extracellular concentration
of 2 (4). (iv) The RPS may react with thiols such as GSH
or MT, which may prevent platination of nuclear DNA
(2, 7-9, 43). The reaction is assumed second-order, with
rate kbSP where S is the concentration of thiol groups in
Figure 8. Model showing the important processes leading to
the platination of genomic DNA by cisplatin. The definitions of
the terms used in the model are as follows: E, extracellular
concentration of cisplatin, 1; kh, rate constant for hydrolysis of
1 to the mono-aquo form, 2; A, sum of concentrations of 2 and
4; ki, rate constant for the conversion of 2 to 4; km, rate constant
for the reaction of 1, 2, and 4 with components in the medium;
kt, rate of uptake of 2 and 4 into the cell; P, cytosolic concentra-
tion of RPS; D, number of available sites on DNA for RPS; kd,
rate constant for the reaction of RPS with DNA; S, total
concentration of cellular thiols; kb, rate constant for the reaction
of cellular thiols with RPS; ke ) rate constant for repair.
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the cytosol, ∼3 mM for GSH plus MT (43), and kb is 0.013
M-1 s-1 for GSH and 0.65 M-1 s-1 for MT reacting with
1 (21, 44, 45). The rates of reaction of 1 and 4 with
nucleophiles should be similar because the leaving groups
are Cl- and OH-, respectively (46), so we approximate
the rate constant for reaction of 4 with cellular thiols as
0.65 M-1 s-1. (v) We assume that Pt crosses the nuclear
membrane by passive diffusion (21, 47) and then reacts
with nuclear DNA by a second-order reaction. The rate
of formation of Pt-DNA adducts is given by kdPD, P
being the intracellular RPS concentration and D being
the number of available DNA sites to which the RPS can
bind. The rate constant for the mono-aquo complex at
pH 6.0 at 25 °C to form a monoadduct with guanine in
an oligonucleotide duplex in vitro has been measured as
1.06 M-1 s-1 (25). However, this does not seem applicable
to the cell because the rate measurements were made
with both reactants uniformly distributed in solution, so
that the process by which the RPS reaches the compart-
ment containing the DNA (the nucleus) was not included.
Rather than add another parameter to the model, we
have chosen to consider transport of RPS to the interior
of the nucleus and subsequent reaction with DNA sites
as a single process, with rate -dD/dt ) kdDP. (vii) The
initial concentration of exposed DNA sites, D0, may be
estimated as follows. The preferred binding site is GG
(1) and about 1/5 of the 5 × 109 bases in the nuclear DNA
are Gs, so there are about 2 × 108 GG binding sites.
Estimating that only about 1% of the bases are exposed
to attack by RPS and that there are other binding sites,
we estimate D0 as 3 × 106. Because the number of Pt
adducts is always much less than D0, D remains ap-
proximately equal to D0, which means only the value of
kdD0, and not the value of D0, is important. Using the
estimated value of D0, we choose the value of kd to give
platination rates comparable to those measured in the
AUC experiments described here. (viii) All species outside
the cell react with the medium, with a first-order rate
constant km ) 0.101 h-1. The value of km is obtained from
NMR measurements of the total [cisplatin] (E + A) as a
function of time in the absence of cells, where A is the
sum of the concentrations of 2 and 4; E + A ) c exp(-
kmt). (ix) Finally, we write the rate of repair as ke(D0 -
D), since D0 - D is the number of adducts. Repair
removes Pt from DNA, increasing D, but does not return
the Pt to the pool of intranuclear RPS. The value of ke
can be estimated from measurements on neuroblastoma
cells by Hagrman and Dubowy (personal communication).
They found that when there were ∼30 Pt-DNA adducts
per 106 nts immediately after incubation with cisplatin,
there were ∼6 Pt-DNA adducts per 106 nt 4 h later.
Thus, 6/30 ) exp(-4ke) and ke ) 0.4 h-1. For the present
calculations, repair is numerically unimportant.
The differential equations resulting from these pro-
cesses are now given. The concentration of 1, E, changes
because of reaction with the medium and conversion to
the aquated forms (2, 4), the total concentration of which
is denoted by A:
Here, Ka is the acid ionization constant of the chloro-aquo
compound 2. The factor [H+]/(Ka + [H+]) is required
because form 1 interconverts with form 2 only (not form
4). Also
Note that dP/dt is in M/h, whereas dD/dt is in millions
of sites/h. The ratio of kd′ to kd is thus the cell volume
(Vcell ) 10-12 L) multiplied by Avogadro’s number and
divided by 106, i.e., 6 × 105. Equations 1-5 are solved
numerically using the Rkadapt function of MathCad,
which uses the Runge-Kutta method with variable step
size.
Figure 9 shows results obtained for an initial concen-
tration of 1 of 25 µΜ, assuming 10 million cells present,
as in the AUC measurements. The upper panel shows
the concentrations of 1 and 2 + 4 outside the cell, as well
dE
dt






Figure 9. Results of calculations using the model of Figure 8.
The initial concentration of cisplatin, 1, ) 65 µΜ. The rate of
transport of aquated cisplatin into a cell is ktA per cell where A
is the concentration (M) of aquated cisplatin (2 + 4) outside the
cells and kt ) 4.2 × 10-13 mol h-1 M-1. Other rate constants
are as follows: kh ) 0.205 h-1 (aquation), ki ) 24.1 M-1 h-1
(reverse to aquation), km ) 0.101 h-1 (reaction with medium),
kb ) 0.65 M-1 h-1 (reaction of Pt with thiols), kd ) 50 M-1 h-1
per site (reaction of Pt with DNA), and ke ) 0.4 h-1 (repair).
The number of available sites is D0 ) 3 × 106. Upper panel:
curves show the concentrations of extracellular cisplatin, 1,
chloro-aquo species 2 + chloro-hydroxy species 4, and intracel-
lular Pt. Lower panel: calculated number of Pt-DNA adducts
as a function of time. The slope (rate of formation of adducts) is
constant for t > ∼0.5 h.
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as the total concentration of Pt inside the cell, vs time.
The concentration of Pt inside the cell becomes larger
than that outside the cell. The concentration of 2 + 4 is
always too small to be seen in the NMR measurements,
even though these species are formed from 1, because
aquated cisplatin passes into the cell as rapidly as it is
formed. At t ) 3 h, corresponding to AUC ) 75 µΜ h,
the number of Pt-DNA adducts is 1.45 × 105, corre-
sponding to 48.4 adducts per million nt (lower panel of
Figure 9). This is calculated based on the total number
of nts in the genome, not only those exposed to platina-
tion, to correspond with what is actually determined in
the AUC experiments. The value of kd, 7 × 103 h-1 M-1
per site, was chosen so that this agrees (see Table 1) with
what is found experimentally.
The thiol concentration (not shown in Figure 9) de-
creases by less than 0.01%, even at 4 h. The extent of
Pt-thiol reaction is small because the value of the rate
constant kb and the RPS concentration are small. The
total number of Pt-DNA adducts is comparable to the
number of Pt-thiol adducts and much less than the
number of Pt atoms in the cytosol. In fact, only about
3% of the Pt in the cell has reacted with nuclear DNA at
3 h. This is about what is stated in the literature, that
∼1% of the cellular Pt is bound to DNA (42). The total
amount of Pt in the cell is mainly determined by the rate
at which 2 or 4 enters the cell.
Calculations with our model show that with 5 million
cells and an original total [cisplatin] of 65 µΜ, A never
exceeds 15 µM. Because the sensitivity of the NMR
experiment (see Figures 6 and 7) prevents measurement
of concentrations below ∼15 µΜ, this explains why the
mono-aquo species is never detected in experiments with
15 million cells. Model calculations with E0 ) 65 µΜ show
that with fewer than 5 million cells, A would exceed 15
µΜ and would be detectable. Experiments (not reported
here) confirm this.
A series of calculations using this model with various
values of E0 and t show that the amount of platina-
tion is proportional to AUC except for very short times.
As seen in Figure 9 (lower panel), the number of ad-
ducts grows at a constant rate for t > 0.5 h. For t < 0.5
h, concentrations of the chloro-aquo species inside
and outside the cell vary rapidly and the rate is not
constant. The constancy of the rate of adduct formation
implies that the amount of platination is proportional to
AUC.
Summary and Conclusions
In this report, we show that for Jurkat cells in culture
exposed to cisplatin, the number of Pt adducts on DNA
is proportional to AUC. Here, AUC is the area under the
concentration vs time curve for unreacted (dichloro)
cisplatin. The number of Pt-DNA adducts is measured
immediately following exposure to drug. We also show
that the number of DNA adducts correlates linearly with
a decrease in respiration, measured 24 h after removal
of drug; there is no effect on respiration immediately after
drug exposure. The number of adducts also correlates
linearly with the amount of DNA fragmentation, mea-
sured 24 h after drug exposure, and with cell viability.
We also report on the use of HSQC NMR to study the
reactions of cisplatin, at concentrations approaching
clinical relevance, in the presence and in the absence of
cells. In the absence of cells (but with cell growth medium
present), the dichloro form 1 is transformed into the
mono-aquo species (kh ) 0.205 h-1 at 37 °C) because the
chloride concentration, originally 154 mM in the cisplatin
stock solution, is lowered to 104 mM in the culture
medium. As seen in the HSQC NMR, the concentration
of the mono-aquo species decreases because of this
transformation and reaction with the components of the
medium. In the presence of cells, the concentration of 1
also decreases (with a somewhat smaller initial rate than
in the absence of cells), reflecting the transformation to
the mono-aquo species. However, the signal for the latter
is not seen because 2 (4) is removed from the medium by
the cells as rapidly as it is formed, keeping its concentra-
tion too low to be measured in these experiments. From
experiments of this type, it is possible to measure the
rate at which the mono-aquo species is accumulated by
cells.
We present a phenomenological model for platination
of nuclear DNA by exposure to cisplatin. The processes
included are aquation of cisplatin outside the cell, pas-
sage of the chloro-aquo species through the cell mem-
brane, reaction of RPS in the cytosol with thiols, forma-
tion of adducts between RPS and accessible DNA sites
in the nucleus, and DNA repair. We have measured
values for the repair rate and for the rate constant for
the hydrolysis of cisplatin at 37 °C in culture medium.
From the equilibrium constant for hydrolysis (29), we
derive the rate constant for the reverse reaction. The rate
constant for the reaction of 4 with thiols at pH 7.4, kb,
was estimated to be the rate constant for the reaction of
1 with cellular thiols (43-45). The uptake rate for Pt,
presumably in the form 2 or 4, by human breast cancer
cells has been measured (42) and is used as an estimate
of the rate at which Pt enters Jurkat cells. The rate
constant kd for the reaction of Pt with nuclear DNA
(actually the rate of Pt transport to the nuclear DNA
followed by its reaction with DNA) is not known. It turns
out that only kdD is important, where D is the number
of available Pt binding sites. Estimating D, we choose a
value of kd in the model to give a number of adducts
comparable to what we found in the AUC experiments.
Despite the approximations and assumptions, the
model helps us to understand our experimental results
and indicates what processes are important. For example,
the model shows under what circumstances the amount
of platination of nuclear DNA is proportional to AUC. It
also shows that most of the Pt in the cell remains
unreacted. The fraction of intracellular Pt that reacts
with intracellular thiols is quite small. This suggests that
thiols contribute to cell protection (and cell resistance)
in ways other than simply reacting with Pt before it
reaches the nuclear DNA. However, it may be that too
small a value was used for the rate constant kb (our value
was obtained from in vitro measurements). Rate con-
stants for reaction of Pt drugs with some drug thiols are
more than an order of magnitude larger (44, 48).
In addition, the model explains why the chloro-aquo
species is not seen in our NMR experiments with 5
million or more cells present and predicts correctly the
maximum number of cells, which can be used if this
species is to be seen. The NMR experiments show that
the species preferentially removed from the culture
medium by Jurkat cells is mostly the mono-aquated form
of the drug, which, at neutral pH, is mostly deprotonated.
Because forms of cisplatin with one or two bound water
molecules are more reactive to nucleophiles than 1, the
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anticancer effects of cisplatin might be enhanced by
administration of aquated forms of the drug directly to
the tumor. The suggestion was made by Howell and co-
workers (39) that a therapeutic strategy be based on
regional intraarterial or intracavity administration of
aquated cisplatin in combination with a systemic neu-
tralizing agent.
It is known that the extracellular pH of tumors is in
the range of 6.0-7.0, while the extra- and intracellular
pH of normal tissue is ∼7.4 (49, 50). Because complex 2
has a pKa for deprotonation of 6.41, the relative amounts
of 2 and 4 found in normal tissue and tumors must be
different. Clearly, additional study will be necessary to
determine if and to what extent pH effects associated
with tumors might contribute to the remarkable ef-
fectiveness of cisplatin for treating cancer.
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